Reuters logo
Actelion shareholders back R&D spinoff, keep J&J deal on track
April 5, 2017 / 11:04 AM / in 6 months

Actelion shareholders back R&D spinoff, keep J&J deal on track

The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Shareholders in Swiss biotech group Actelion (ATLN.S) approved on Wednesday spinning off its drug discovery and early clinical pipeline into a new company, keeping Johnson & Johnson’s (JNJ.N) $30 billion (24.03 billion pounds) takeover on track to close in the second quarter.

“After a very successful two decades, resulting in an unprecedented share price increase of more than 2,000 percent since our IPO, the next chapter for Actelion awaits,” Chairman Jean-Pierre Garnier said after the annual meeting.

“With the successful tender offer by Johnson & Johnson, regulatory approvals on track, and today’s approval by the shareholders to spin out Idorsia, the transaction is moving ahead at full steam.”

Johnson & Johnson last month declared its tender offer a success and reported it controlled 77.2 percent of Actelion’s voting rights after the main offer period.

J&J intends to delist Actelion, while the new research and development company led by Actelion founder Jean-Paul Clozel will have a separate Swiss listing.

Reporting by Michael Shields; Editing by Brenn Hughes Neghaiwi

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below